Virtual Library

Start Your Search

Maria Paraskeva

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-95 - EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer (ID 12177)

      12:00 - 13:30  |  Author(s): Maria Paraskeva

      • Abstract


      Patients with epidermal growth factor (EGFR)-mutant non-small cell lung cancer (NSCLC) represent a distinct treatment and prognostic subgroup, typically responding to treatment with tyrosine-kinase inhibitors (TKIs) but also displaying a highly variable prognosis. We herein aimed to further investigate the potential value of EGFR genotype as a predictor of survival in EGFR-mutant NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The medical records of 68 patients with NSCLC and positive EGFR mutation status, who had been treated with EGFR-TKIs, were retrospectively reviewed. Demographic, clinicopathological features and EGFR mutation testing results of patients were correlated with survival.

      4c3880bb027f159e801041b1021e88e8 Result

      (EGFR) exon 19 E746-A750 deletion and (EGFR) exon 21 L858R point mutation were the commonest EGFR mutations, observed in 58% and 24% of patients, respectively. Median progression-free survival (PFS) among patients with (EGFR) exon 21, 19 and 18/20 was 22.9, 13.9 and 4.7 months, respectively. Median overall survival (mOS) for the above subgroups was 25.1, 35.8 and 13.8 months, respectively. The presence of (EGFR) exon 21 L858R point mutation was correlated with reduced risk of disease recurrence as compared to (EGFR) 18/20 mutations (HR=0,25, p=0,018); patients with (EGFR) exon 19 mutations had reduced risk of death as compared to those with (EGFR) exon 18/20 mutations (HR=0,29, p=0,007).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The presence of (EGFR) exon 19 mutations may be associated with increased OS among patients with EGFR-mutant NSCLC.